AtriCure Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
AtriCure Inc. (ATRC) PT Raised to $92 at Needham & Company
November 4, 2021 6:44 AM EDTNeedham & Company analyst Mike Matson raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $92.00 (from $90.00) while maintaining a Buy rating.
The analyst commented, "ATRC's 3Q21 revenue, EBITDA, and EPS all beat consensus. While it has only been 6 months since EPi-Sense's FDA... More
AtriCure (ATRC) Tops Q3 EPS by 10c
November 3, 2021 4:39 PM EDTAtriCure (NASDAQ: ATRC) reported Q3 EPS of ($0.23), $0.10 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $70.5 million versus the consensus estimate of $68.68 million.
GUIDANCE:
AtriCure sees FY2021 EPS of ($1.20), versus the consensus of ($1.35). AtriCure... More
